

UCLA

UCLA Previously Published Works

Title

Correction.

Permalink

<https://escholarship.org/uc/item/45v3b70s>

Journal

Artificial cells, nanomedicine, and biotechnology, 47(1)

ISSN

2169-1401

Authors

Asadi, N
Annabi, N
Mostafavi, E
et al.

Publication Date

2019-12-01

DOI

10.1080/21691401.2019.1639941

Peer reviewed

Synthesis, characterization and *in vitro* evaluation of magnetic nanoparticles modified with PCL-PEG-PCL for controlled delivery of 5FU

Nahideh Asadi, Nasim Annabi, Ebrahim Mostafavi, Maryam Anzabi, Rovshan Khalilov, Siamak Saghfi, Masoud Mehrizadeh & Abolfazl Akbarzadeh

To cite this article: Nahideh Asadi, Nasim Annabi, Ebrahim Mostafavi, Maryam Anzabi, Rovshan Khalilov, Siamak Saghfi, Masoud Mehrizadeh & Abolfazl Akbarzadeh (2018) Synthesis, characterization and *in vitro* evaluation of magnetic nanoparticles modified with PCL-PEG-PCL for controlled delivery of 5FU, Artificial Cells, Nanomedicine, and Biotechnology, 46:sup1, 938-945, DOI: [10.1080/21691401.2018.1439839](https://doi.org/10.1080/21691401.2018.1439839)

To link to this article: <https://doi.org/10.1080/21691401.2018.1439839>



Published online: 22 Feb 2018.



Submit your article to this journal [↗](#)



Article views: 326



View Crossmark data [↗](#)



Citing articles: 2 View citing articles [↗](#)



Synthesis, characterization and *in vitro* evaluation of magnetic nanoparticles modified with PCL–PEG–PCL for controlled delivery of 5FU

Nahideh Asadi^{a,b}, Nasim Annabi^{c,d,e}, Ebrahim Mostafavi^e, Maryam Anzabi^{f,g}, Rovshan Khalilov^{h,i}, Siamak Saghi^{h,i}, Masoud Mehrizadeh^j and Abolfazl Akbarzadeh^{a,e,h,k}

^aTuberculosis and Lung Disease Research Center of Tabriz, Tabriz University of Medical Sciences, Tabriz, Iran; ^bStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; ^cBiomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA; ^dHarvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA; ^eDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA; ^fCenter of Functionally Integrative Neuroscience (CFIN) and MINDLab, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; ^gDepartment of Radiology, Neurovascular Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA; ^hJoint Ukrainian-Azerbaijan International Research and Education Center of Nanobiotechnology and Functional Nanosystems, Drohobych Ukraine & Baku, Azerbaijan; ⁱDepartment of Plant Physiology, Faculty of Biology, Baku State University, Baku, Azerbaijan Republic; ^jDepartment of Petroleum engineering, School of engineering and Applied Sciences, Khazar University, Baku, Azerbaijan; ^kUniversal Scientific Education and Research Network (USERN), Tabriz, Iran

ABSTRACT

Magnetic nanoparticles have properties that cause to apply them in cancer therapy and vehicles for the delivery of drugs such as 5FU, especially when they are modified with biocompatible copolymers. The aim of this study is to modify superparamagnetic iron oxide nanoparticles (SPIONPs) with PCL–PEG–PCL copolymers and then utilization of these nanoparticles for encapsulation of anticancer drug 5FU. The ring-opening polymerization (ROP) was used for the synthesis of PCL–PEG–PCL copolymer by ϵ -caprolactone (PCL) and polyethylene glycol (PEG2000). We used the double emulsion method (water/oil/water) to prepare 5FU-encapsulated Fe₃O₄ magnetic nanoparticles modified with PCL–PEG–PCL copolymer. Chemical structure and magnetic properties of 5FU-loaded magnetic-polymer nanoparticles were investigated systematically by employing FT-IR, XRD, VSM and SEM techniques. *In vitro* release profile of 5FU-loaded NPs was also determined. The results showed that the encapsulation efficiency value for nanoparticles were 90%. Moreover, the release of 5FU is significantly higher at pH 5.8 compared to pH 7.4. Therefore, these nanoparticles have sustained release and can apply for cancer therapy.

ARTICLE HISTORY

Received 6 December 2017
Revised 7 February 2018
Accepted 8 February 2018

KEYWORDS

Magnetic nanoparticles;
PCL–PEG;5FU

Introduction

Drug delivery systems have some drawbacks. For example, oral drug delivery systems that are extremely important to the field of medicine, because the largest part of the common illnesses is treated by oral route of medication, they have some defects such as low solubility in aqueous solutions and low penetration across intestinal membranes [1]. The gastrointestinal system has problems for protein drug delivery. Also cancer chemotherapeutics due to their nonselective activity are less effective to cure tumours so resulting in dose limiting side effects [2,3].

Drug delivery systems have modified with new therapeutic molecules such as nucleic acids, peptides and others to improve themselves. Moreover, some of these systems give a stable concentration of drug in the bloodstream for a long period of time that is attractive for the treatment of some diseases, and there is factual evidence of patients' indicating improvement during this treatment [4]. Drug delivery with controlled rate, sustain release and targeted delivery are other very attractive ways and have been pursued remarkably [5,6].

Recent progresses in the applying of carriers for sustain and target drug delivery, micro- and nano-systems [7,8], bio-recognizable structures, micro-needles for transdermal drug delivery lead to improve permeability and flexibility of these polymeric materials. In the smart drug delivery systems, micro- and nanoparticles can hold and release diverse active agents on demand [9]. The main purposes of nanoparticles in a drug delivery system are controlling: surface properties, particle size and release of pharmacologically active ingredients in the way to get the drug at the targeted site in the optimal rate and dose procedure [10,11]. Systems based on drug delivery can provide improved efficacy and decreased toxicity for anticancer agents. Long blood circulation result in carriers can use the "enhanced permeability and retention" (EPR) effect for special extravasation from tumour vessels [12]. Drug-loaded nanoparticles transport therapeutics to tumour sites undergo a multistep process to achieve their therapeutic target, launch with extravasation from leaky tumour vessels [13] (see Figure 1).

Various nanosystems have been studied as drug delivery systems such as polymeric micelles, polymeric nanoparticles,




Figure 1. Image of multivalent targeting in nanoparticle drug delivery [13].

nanogels, nanocapsules, fullerenes, solid lipid nanoparticles (SLN), nanoliposomes, dendrimers, quantum dots and metal nanoparticles [6,14]. Magnetic nanoparticles (MNPs) have received much attention due to their unique physical properties, biocompatibility, magnetic susceptibility, stability and their role in the cellular and molecular level of biological interactions. In addition, MNPs are easily controlled by an exterior magnetic field application, which offer the releasing of the anticancer agent at an exact rate and at a specific site, overcoming the problems of conformist techniques for diagnosis and therapy. These properties cause the magnetic nanoparticles be suitable in biomedical fields, such as, drug delivery, hyperthermia treatment [15–17].

Polymeric nanoparticles have benefits for drug delivery such as encapsulation of bioactive molecules and protection them from enzymatic and hydrolytic degradation [6,18–21]. Therapeutically polymeric nanoparticles that used are composed of biocompatible or biodegradable materials, like poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(ϵ -caprolactone) (PCL), alginic acid, chitosan and gelatin [22–26]. Specially, amphiphilic, thermosensitive ones for example BAB and ABA tri-block or AB di-block consisting of hydrophobic (B) and hydrophilic (A) blocks have been researched more than other smart systems because of their *in situ* gel-forming properties at body temperature [27–29]. Polycaprolactone (PCL) is a hydrophobic, biodegradable, semi-crystalline polymer. The suitable solubility of this polymer, its low melting point and amazing blend-compatibility have encouraged wide studies into its possible uses in the biomedical field like packaging, medical implant, and controlled drug delivery [30,31].

The purpose of this work was to evaluate the magnetic-PCL-PEG-PCL nanoparticles as anticancer drug carriers. Firstly, Fe_3O_4 magnetic nanoparticles were prepared and then the PCL_{1000} - PEG_{2000} - PCL_{1000} triblock copolymer was synthesized with ring opening polymerization by ϵ -caprolactone and PEG and stannous octoate as catalyst [32]. Then, 5FU was encapsulated in Fe_3O_4 -PCL-PEG-PCL nanoparticles by the




Figure 2. Preparation of magnetic nanoparticles.

double emulsion method (w/o/w). The physicochemical properties of nanoparticles and *in vitro* release of 5FU were characterized [33–38].

Experimental section

Materials and methods

Ferric chloride hexahydrate ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$), ferrous chloride tetrahydrate ($\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$) and ammonium hydroxide (32 wt.%) were purchased from Fluka (Buchs, Switzerland). ϵ -Caprolactone (ϵ -Cl), stannous octoate ($\text{Sn}(\text{Oct})_2$) and polyethylene glycol (PEG) (molecular weight 2000) were purchased from Sigma Aldrich (St. Louis, MO). Infrared spectra were recorded with BRUKER series FTIR. The magnetic property was measured on a vibrating sample magnetometer (Meghnatis Daghigh Kavir, Iran) at a maximum magnetic field of 10 kOe at room temperature [39]. X-ray diffraction and scanning electron microscopy (SEM) measurements were conducted using VEGA and TESCAN, respectively. The drug




Figure 3. Fourier transform infrared spectra of magnetic nanoparticles.

encapsulation efficiency and release profile were determined by an ultra violet visible spectrometer (Shimadzu, Tokyo, Japan).

Preparation of superparamagnetic nanoparticles

Chemical coprecipitation method was used for the synthesis of magnetic nanoparticles [40]. Giving to this method, 0.7418 g of $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$ (4 mmol) and 0.2242 g of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ (7 mmol) were dissolved in 10 ml of deionized water, such that the ratio of $\text{Fe}^{2+}/\text{Fe}^{3+}$ was 1.75:1, respectively. This solution was stirred under nitrogen at 85°C for 1 h. In the next step, 22.5 ml $\text{NH}_3 \cdot \text{H}_2\text{O}$ (25%) was added into the solution quickly, stirred under nitrogen for 1 h, and then cooled at room temperature. Finally, the precipitated particles were washed three times with water and dried under vacuum at 70°C (see Figure 2).

Synthesis of (PCL₁₀₀₀-PEG₂₀₀₀-PCL₁₀₀₀) triblock copolymer

PCL₁₀₀₀-PEG₂₀₀₀-PCL₁₀₀₀ copolymer was prepared by ring opening polymerization. $\text{Sn}(\text{Oct})_2$ was a catalyst of reaction. A 7.4 g of ϵ -caproate lactone and 5 g of polyethylene glycol with a molecular weight of 2000 (PEG₂₀₀₀) were weighed and in a bottleneck flask were heated to 120°C under a nitrogen atmosphere to complete melting. Then 1 ml of 0.05% (w/w) stannous octoate was added and the temperature was raised to 130°C . This temperature was continued for 2 h. The polymerization was carried out under vacuum [41].

Preparation of 5FU encapsulated Fe_3O_4 magnetic nanoparticles modified with PCL-PEG-PCL copolymer

We used double emulsion method (water/oil/water) for encapsulation of 5FU in Fe_3O_4 -PCL-PEG-PCL modified nanoparticles. Firstly, an aqueous solution of 5FU (2.5 mg/2.5 ml) was added to dichloromethane, that 120 mg of the PCL-PEG-PCL copolymer and 5 mg of the Fe_3O_4 nanoparticles had been dissolved in it, using a sonication at 20,000 rpm for 25 s, the w/o emulsion was created. Then w/o emulsion was

added to a 50 ml aqueous solution of PVA (polyvinyl alcohol) 0.5% and the mixture was sonicated at 70,000 rpm for 2 min to make w/o/w emulsion. The w/o/w emulsion was stirred at room temperature to evaporate the organic phase (Heidolph Instruments, Hei-VAP Series, Schwabach, Germany). In order to purify the nanoparticles, two cycles of centrifugation (10,000 rpm for 1 h in a Biofuge 28 RS, Heraeus centrifuge) was used. Then the precipitate and solution were separated. Nanoparticles was dried by freeze-drying and supernatant solution was used to measure the concentration of encapsulated drug. Finally, the nanoparticles were filtered through a 1.2 mm filter (Millipore, Bedford, MA). To determine the encapsulation efficiency of 5FU in modified Fe_3O_4 magnetic nanoparticles, nanoparticles were disintegrated in dichloromethane [42]. The 5FU concentration was determined by spectrophotometer at 266 nm. Drug encapsulation efficiency was obtained with the following equation:

Encapsulation efficiency (%)

$$= (\text{Drug total} - \text{Drug supernatant}) / \text{Drug total} \times 100$$

Nanoparticle characterization

FTIR spectrophotometer (BRUKER series) was used for recording infrared spectra. For this purpose, the samples and KBr were pressed to form a tablet. In order to analysis the crystal structure of the Fe_3O_4 magnetic nanoparticles, power X-ray diffraction (Rigaku D/MAX-2400 X-ray diffractometer) was applied. The magnetization curves of the samples were measured by vibrating sample magnetometry at room temperature. To determine the size and morphology of the nanoparticles, SEM was used by VEGA/TESCAN.

In vitro drug release profile study

For this purpose, 3 mg of 5FU-encapsulated modified magnetic nanoparticles was dispersed in 30 ml of phosphate buffered solution (pH 7.4). Samples were incubated in 37°C .




Figure 4. Fourier transform infrared spectra of 5FU encapsulated Fe_3O_4 magnetic nanoparticles modified with PCL-PEG-PCL copolymer.

In determined time intervals, 3 ml of samples were removed and analyzed with ultraviolet spectrofluorometry (Shimadzu, Tokyo, Japan) and same volume of fresh phosphate-buffered solution was reconstituted. The samples were analyzed with ultraviolet spectrofluorometry to calculate the amount of released 5FU (λ_{ex} 470 nm and λ_{em} 585 nm). To investigate the effect of pH on drug release, the test was repeated in acidic acetate buffer solution (pH = 8.5) and at temperature 40 °C.

Results and discussion

Characterization of nanoparticles

The encapsulation efficiency value achieved for 5FU was:

$$\text{EE\%} = (\text{Drug total} - \text{Drug supernatant}) / \text{Drug total} \times 100$$

$$\text{EE \%} = [(5 - 0.382) / 5] \times 100 = 90\%$$

FTIR spectroscopy

The structure confirmation of Fe_3O_4 and PCL-PEG-PCL copolymer was studied by FTIR spectroscopy. From the infrared spectra shown in Figure 3, the absorption peaks at 580 cm^{-1} belonged to the stretching vibration mode of Fe-O bonds in Fe_3O_4 , 3402 cm^{-1} belonged to free hydroxyl group (OH) of Fe_3O_4 . The peaks at 2869 cm^{-1} and 2950 cm^{-1} are due to C-H stretch. Absorption at 933 cm^{-1} and 1247 cm^{-1} belonged to C-O stretch. $1750\text{--}1765\text{ cm}^{-1}$ is assigned to C=O, $1090\text{--}1300\text{ cm}^{-1}$ assigned to C-C, C-O and $1085\text{--}1150\text{ cm}^{-1}$ is due to polyethylene glycol ether band (see Figures 4 and 5).

X-ray diffraction patterns

The X-ray diffraction was used to study the crystal structure of the Fe_3O_4 nanoparticles. This provides patterns for pure Fe_3O_4 magnetic nanoparticles and 5FU-encapsulated modified magnetic nanoparticles. The characteristic diffraction peaks are indicated, respectively, by their indices (2 2 0), (3 1 1), (4 0 0), (4 2 2), (5 1 1) and (4 4 0), which could be well indexed to the inverse cubic spinel structure of Fe_3O_4 (JCPDS card 85-1436). Characteristic diffraction peaks were also observed for 5FU-encapsulated Fe_3O_4 magnetic nanoparticles modified with PCL-PEG-PCL copolymer. This determines that modification of the Fe_3O_4 nanoparticles did not lead to any crystal phase change. The average crystallite size D was about 10 nm and obtained from the Sherrer equation $D_{k\lambda} = 0.9\lambda / (\beta \cos\theta)$ where K is the constant, λ is the X-ray wavelength and β is the peak width of half-maximum (see Figures 6 and 7).

Magnetic properties

The magnetic properties of Fe_3O_4 nanoparticles were determined with VSM at room temperature. Figure 8 displays the hysteresis loops of the samples. For 5FU-encapsulated Fe_3O_4 magnetic nanoparticles modified with copolymer, the saturation magnetization is 18 emu/g, which is less than the pure Fe_3O_4 nanoparticles (61 emu/g). This difference recommends that a large amount of copolymer modified magnetic nanoparticles and 5FU. It is possible to separate 5FU-encapsulated modified Fe_3O_4 nanoparticles from the reaction medium by using a magnetic field. This is due to the large saturation magnetization. In addition, there was no hysteresis in the magnetization, with both remanence and coercivity being zero, indicating that these magnetic nanoparticles have superparamagnetic properties [43].




Figure 5. (a) Fourier transform infrared spectra of PCL-PEG-PCL copolymer. (b) Comparative Fourier transform infrared spectra of synthesized copolymer (PCL-PEG-PCL) with FT-IR spectra of its polymers.




Figure 6. XRD spectra of Fe₃O₄ magnetic nanoparticles.

SEM analysis

The size and surface morphology of the nanoparticles was observed by SEM. Figure 9(a,b) shows micrographs of pure Fe₃O₄ nanoparticles and 5FU-encapsulated Fe₃O₄ modified nanoparticles, respectively. As it can be seen, the photograph demonstrates that nanoparticles are well aggregated, which was due to the nanosize of the Fe₃O₄ of about 10 nm. After modification of magnetic nanoparticles with PCL-PEG-PCL copolymer and encapsulation of 5FU, the size of the particles changed, and dispersion of the particles was greatly improved (Figure 9(b)), which can be due the electrostatic repulsion force and steric hindrance between the copolymer chains on the encapsulated Fe₃O₄ nanoparticles.

In vitro drug release profile

The release profiles of 5FU were achieved by the ratio of 5FU release with respect to the total amount of 5FU encapsulated. Releasing 5FU from nanoparticles has two phases: burst release in initial and sustain release after 12 h. A major amount of drug released within 12 h. This was 33.1% for Fe₃O₄ magnetic nanoparticles modified with PCL-PEG-PCL (Figure 10). The total release amount of 5FU over 2 days was 81.4% from Fe₃O₄-PCL-PEG-PCL. The 5FU release rate from the Fe₃O₄-PCL-PEG-PCL nanoparticles was also pH-dependent and improved at pH 5.8. In a drug releasing, several processes are involvement, containing distribution through the polymer matrix, release by polymer degradation, and




Figure 7. XRD spectra of PCL₁₀₀₀-PEG₂₀₀₀-PCL₁₀₀₀ copolymer.




Figure 8. Magnetic behaviour of magnetic nanoparticles.

solubilization and diffusion through microchannels that exist in the polymer matrix or are formed by erosion [44,45]).

Conclusion

Nanotechnology-based drug delivery can modify cancer treatment by improving distribution and accumulation of several drugs in the disease sites. Targeted drug delivery in cancer by hyperthermia *via* magnetic nanoparticles has functional characteristics such as small size, low toxicity, high stability, simple purification and sterilization [46–49]. In this work, we encapsulated 5FU in an improved and less-toxic carrier. In order to minimize undesired uptake or interactions in unusual sites, a biodegradable nanocarrier based on magnetic

nanoparticles and copolymer has been developed for 5FU. Quantity and location of drug release are controlled by the PCL-PEG-PCL-coated magnetic nanoparticles and pH. This nanosystem can be used for targeting a wide variety of solid tumours. There are some parameters that effect on encapsulation efficiency such as copolymer concentration in organic solution, volume of the outer aqueous phase, volume of the internal aqueous phase, 5FU concentration in the inner aqueous phase, the first and second homogenized speed and time. The encapsulation efficiency (EE) was 90%. It is indicated that the 5FU-encapsulated Fe₃O₄-PCL-PEG-PCL nanoparticles have pH sensitive property and can be used for targeting extracellular pH of cancer cells and could be an effective carrier for anticancer drugs delivery.




Figure 9. (a) SEM image of Fe_3O_4 nanoparticles and (b) 5FU-encapsulated Fe_3O_4 magnetic nanoparticles modified with PCL-PEG-PCL copolymer.




Figure 10. *In vitro* release experiment.

Overall, modification of the magnetic nanoparticles could be possible useful for drug delivery systems. Our results explain that Fe_3O_4 magnetic nanoparticles modified with PCL-PEG-PCL could be a valuable carrier for drug delivery.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

The authors are grateful for support from the National Institute for Medical Research Development (NIMAD), [Grant no. 958659].

References

- [1] Liu L, Fishman ML, Kost J, et al. Pectin-based systems for colon-specific drug delivery via oral route. *Biomaterials*. 2003;24: 3333–3343.
- [2] Jevprasesphant R, Penny J, Attwood D, et al. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. *Pharm Res*. 2003;20:1543–1550.
- [3] Thomas TP, Patri AK, Myc A, et al. *In vitro* targeting of synthesized antibody-conjugated dendrimer nanoparticles. *Biomacromolecules*. 2004;5:2269–2274.
- [4] Miao B, Song C, Ma G. Injectable thermosensitive hydrogels for intra-articular delivery of methotrexate. *J Appl Polym Sci*. 2011; 122:2139–2145.
- [5] Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliv Rev*. 2002;54:631–651.

- [6] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf B: Biointerfaces*. 2010;75:1–18.
- [7] Dai M, Xu X, Song J, et al. Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice. *Cancer Lett*. 2011;312:189–196.
- [8] Cao X, Lai S, Lee LJ. Design of a self-regulated drug delivery device. *Biomed Microdevices*. 2001;3:109–118.
- [9] Kasagana V. Recent advances in smart drug delivery systems. *Int J Nov Drug Deliv Tech*. 2011;1:201–207.
- [10] Alimohammadi YH, Joo SW. PLGA-based nanoparticles as cancer drug delivery systems. *Asian Pac J Cancer Prev*. 2014;15:517–535.
- [11] Vila A, Sanchez A, Tobo M, et al. Design of biodegradable particles for protein delivery. *J Control Release*. 2002;78:15–24.
- [12] Thacharodi D, Rao KP. Development and in vitro evaluation of chitosan-based transdermal drug delivery systems for the controlled delivery of propranolol hydrochloride. *Biomaterials*. 1995;16:145–148.
- [13] Darrell J. One nanoparticle, one kill. *Nature Mater*. 2011;10:342–343.
- [14] Yang Y, Guo Q, Peng J, et al. Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging. *J Biomed Nanotechnol*. 2016;12:1963–1974.
- [15] Shabestari Khiabani S, Farshbaf M, Akbarzadeh A, et al. Magnetic nanoparticles: preparation methods, applications in cancer diagnosis and cancer therapy. *Artif Cells Nanomed Biotechnol*. 2017;45:6–17.
- [16] Li X, Feng J, Zhang R, et al. Quaternized chitosan/alginate-Fe₃O₄ magnetic nanoparticles enhance the chemosensitization of multi-drug-resistant gastric carcinoma by regulating cell autophagy activity in mice. *J Biomed Nanotechnol*. 2016;12:948–961.
- [17] Peng J, Qi T, Liao J, et al. Mesoporous magnetic gold “nanoclusters” as theranostic carrier for chemo-photothermal co-therapy of breast cancer. *Theranostics*. 2014;4:678.
- [18] Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. *Nanoscale Res Lett*. 2012;7:144.
- [19] Akbarzadeh A, Mikaeili H, Zarghami N, et al. Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. *Int J Nanomed*. 2012;7:511.
- [20] Akbarzadeh A, Samiei M, Joo SW, et al. Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. *J Nanobiotechnol*. 2012;10:46.
- [21] Liao J, Wei X, Ran B, et al. Polymer hybrid magnetic nanocapsules encapsulating IR820 and PTX for external magnetic field-guided tumor targeting and multifunctional theranostics. *Nanoscale*. 2017;9:2479–2491.
- [22] Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. *Biomaterials*. 2007;28:869–876.
- [23] Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. *Proc Nat Acad Sci*. 2008;105:2586–2591.
- [24] Szłęk J, Paclawski A, Lau R, et al. Heuristic modeling of macromolecule release from PLGA microspheres. *Int J Nanomed*. 2013;8:4601.
- [25] Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier – systematic examination of fabrication conditions for efficient loading and release. *Colloids Surf B Biointerfaces*. 2007;59:24–34.
- [26] Cui Y, Zhang M, Zeng F, et al. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. *ACS Appl Mater Interfaces*. 2016;8:32159–32169.
- [27] He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. *J Control Release*. 2008;127:189–207.
- [28] Ruel-Gariepy E, Leroux J-C. In situ-forming hydrogels—review of temperature-sensitive systems. *Eur J Pharm Biopharm*. 2004;58:409–426.
- [29] Khodaverdi E, Farhadi F, Jalali A, et al. Preparation and investigation of poly (N-isopropylacrylamide-acrylamide) membranes in temperature responsive drug delivery. *Iran J Basic Med Sci*. 2010;13:102–110.
- [30] Avella M, Bondioli F, Cannillo V, et al. Poly(ϵ -caprolactone)-based nanocomposites: Influence of compatibilization on properties of poly(ϵ -caprolactone)-silica nanocomposites. *Compos Sci Technol*. 2006;66:886–894.
- [31] Skoglund P, Fransson Å. Continuous cooling and isothermal crystallization of polycaprolactone. *J Appl Polym Sci*. 1996;61:2455–2465.
- [32] Labet M, Thielemans W. Synthesis of polycaprolactone: a review. *Chem Soc Rev*. 2009;38:3484–3504.
- [33] Davaran S, Rashidi MR, Pourabbas B, et al. Adriamycin release from poly(lactide-co-glycolide)-polyethylene glycol nanoparticles: synthesis, and in vitro characterization. *Int J Nanomedicine*. 2006;1:535.
- [34] Davaran S, Rashidi MR, Khandaghi R, et al. Development of a novel prolonged-release nicotine transdermal patch. *Pharmacol Res*. 2005;51:233–237.
- [35] Tabrizi MHN, Davaran S, Entezami AA, et al. Synthesis of diclofenac polymeric prodrugs and their hydrolysis reactivity. *Iran Polym J*. 1996;5:243–249.
- [36] Khalilov RI, Nasibova AN, Serezhnikov VA, et al. Accumulation of magnetic nanoparticles in plants grown on soils of Apsheron peninsula. *Biophysics*. 2011;56:316–322.
- [37] Khalilov RI, Ahmadov IS, Kadirov SG. Two types of kinetics of membrane potential of water plant leaves illuminated by ultraviolet light. *Bioelectrochemistry*. 2002;58:189–191.
- [38] Khalilov RI, Khomutov GB, Tikhonov AN. Effect of ultraviolet radiation on structural-functional characteristics of the thylakoid membrane. *Russian Plant Physiol*. 1993;3:338–342.
- [39] Mostafavi E, Ataie A, Ahmadzadeh M, et al. Synthesis of nano-structured Bi_{1-x}BaxFeO₃ ceramics with enhanced magnetic and electrical properties. *Mater Chem Phys*. 2015;162:106–112.
- [40] Mostafavi E, Babaei A, Ataie A. Synthesis of nano-structured La_{0.6}Sr_{0.4}Co_{0.2}Fe_{0.8}O₃ perovskite by co-precipitation method. *J Ultrafine Grained Nanostruct Mater*. 2015;48:45–52.
- [41] Yang J, Park S-B, Yoon H-G, et al. Preparation of poly ϵ -caprolactone nanoparticles containing magnetite for magnetic drug carrier. *Int J Pharm*. 2006;324:185–190.
- [42] Ebrahimi E, Akbarzadeh A, Abbasi E, et al. Novel drug delivery system based on doxorubicin-encapsulated magnetic nanoparticles modified with PLGA-PEG1000 copolymer. *Artif Cells, Nanomed Biotechnol*. 2016;44:290–297.
- [43] Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *Am J Human Genetics*. 1998;62:676–689.
- [44] Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation. *Microbiol Mol Biol Rev*. 2002;66:407–425.
- [45] Liu Y, Dong X-I, Tian C, et al. Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. *Diagn Pathol*. 2012;7:34.
- [46] Chavanpatil MD, Khair A, Panyam J. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules. *Pharm Res*. 2007;24:803–810.
- [47] Nidhin M, Indumathy R, Sreeram K, et al. Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. *Bull Mater Sci*. 2008;31:93–96.
- [48] Chouhan R, Bajpai A. Real time in vitro studies of doxorubicin release from PHEMA nanoparticles. *J Nanobiotechnol*. 2009;7:5.
- [49] Yadav AK, Mishra P, Mishra AK, et al. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. *Nanomed: Nanotechnol Biol Med*. 2007;3:246–257.